Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement.
JSON
Saibene AM, Allevi F, Ayad T, Baudoin T, Bernal-Sprekelsen M, Briganti G, Carrie S, Cayé-Thomasen P, Dahman Saidi S, Dauby N, Fenton J, Golusiński W, Klimek L, Leclerc A, Longtin Y, Mannelli G, Mayo-Yáñez M, Meço C, Metwaly O, Mouawad F, Niemczyk K, Pedersen U, Piersiala K, Plzak J, Remacle M, Rommel N, Saleh H, Szpecht D, Tedla M, Tincati C, Tucciarone M, Zelenik K, Lechien JR
Eur Arch Otorhinolaryngol - (-) - [2021-04-15; online 2021-04-15]
SARS-CoV-2 vaccines are a key step in fighting the pandemic. Nevertheless, their rapid development did not allow for testing among specific population subgroups such as pregnant and breastfeeding women, or elaborating specific guidelines for healthcare personnel working in high infection risk specialties, such as otolaryngology (ORL). This clinical consensus statement (CCS) aims to offer guidance for SARS-CoV-2 vaccination to this high-risk population based on the best evidence available. A multidisciplinary international panel of 33 specialists judged statements through a two-round modified Delphi method survey. Statements were designed to encompass the following topics: risk of SARS-Cov-2 infection and use of protective equipment in ORL; SARS-Cov-2 infection and vaccines and respective risks for the mother/child dyad; and counseling for SARS-CoV-2 vaccination in pregnant, breastfeeding, or fertile healthcare workers (PBFHW). All ORL PBFHW were considered as the target audience. Of the 13 statements, 7 reached consensus or strong consensus, 2 reached no consensus, and 2 reached near-consensus. According to the statements with strong consensus otorhinolaryngologists-head and neck surgeons who are pregnant, breastfeeding, or with childbearing potential should have the opportunity to receive SARS-Cov-2 vaccination. Moreover, personal protective equipment (PPE) should still be used even after the vaccination. Until prospective evaluations on these topics are available, ORL-HNS must be considered a high infection risk specialty. While the use of PPE remains pivotal, ORL PBFHW should be allowed access to SARS-CoV-2 vaccination provided they receive up-to-date information.
PubMed 33855628
DOI 10.1007/s00405-021-06794-6
Crossref 10.1007/s00405-021-06794-6
pii: 10.1007/s00405-021-06794-6
pmc: PMC8046580